CLEVELAND, Nov. 13 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) announced today that the technology of multispectral imaging was ranked as a Top Ten Medical Innovation at Cleveland Clinic's 6th Annual Medical Innovations Summit.
(Photo: http://www.newscom.com/cgi-bin/prnh/20081113/NETH122 )
During the recognition presentation, Dr. Jennifer Hunt, head of surgical pathology at the Cleveland Clinic stated, "When we're talking about tumors, we're talking about what information can we gain about that tumor to guide and direct therapy, prognosis, diagnostics. We believe this technology to be a game changer. It will take personalized medicine to an entirely new level. This is not a step, but a leap. Being able to analyze multiple markers in a single cell to understand the behavior of actual signaling pathways will significantly aid in disease diagnosis and therapy development." Dr. Hunt went on to add, "I expect that this technology will be rapidly adopted across the field of pathology."
The list of devices and technologies was selected by a panel of physicians and scientists affiliated with the Cleveland Clinic, and was unveiled during the annual Medical Innovation Summit this week.
"We are honored and grateful that this technology was recognized by the Clinic," says George Abe, CEO of CRi. "We are dedicated to developing comprehensive solutions that will help produce breakthroughs in biomedical research and medical care."
As biological imaging becomes more about studying complex systems rather than single events, CRi's Nuance system allows users to monitor more than one event or target at a time. The system produces clear and accurate unmixed images from a multi-label tissue section, whether the tissue is labeled for cellular, nuclear, or membrane markers that overlap spatially or spectrally.
"Our Nuance technology is like enabling a colorblind person to see color for the first time," adds Clifford Hoyt, Chief Technology Officer of CRi. "Among other things, it can be used by both pre-clinical and clinical research scientists to reveal new data to expedite targeted therapies, and by physicians for personalized treatment."
Four major criteria served as the basis for qualifying and selecting Cleveland Clinic's Top 10 Medical Innovations. To receive consideration, a nominated innovation was required to: have significant potential for short- term clinical impact, have a high probability of success, be on the market or close to being introduced, and have sufficient data available to support its nomination.
Cambridge Research & Instrumentation, Inc (CRi) is a Boston-based biomedical imaging company providing innovative optical imaging solutions for more than 20 years. CRi's multidisciplinary team is dedicated to providing comprehensive solutions that enable customers to produce breakthroughs in research and medical care. CRi technology helps extract new disease-specific information from biological and clinical samples in the physiological, morphological, and biochemical context of intact tissues and organisms.
With over 80 patents pending and issued, CRi's award-winning innovations are being utilized around the world in a wide range of settings, ranging from academic researcher to pharmaceutical drug development to clinical medicine. CRi is headquartered in Woburn, Massachusetts, and operates a state-of-the-art manufacturing facility and is able to rapidly design and manufacture system- level solutions for a variety of growing market applications.
Visit http://www.cri-inc.com/nuance to find out more about the Nuance system.
CONTACT: Ross Nakatsuji, CRi Marketing-Sales Group Leader, +1-781-935-
9099, ext. 177, or +1-781-405-4000 (cell), rnakatsuji@cri-inc.com
Web site: http://www.cri-inc.com/
